SCHEMBL278150

SCHEMBL278150

O=[C]CN1C(=O)CCC1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 3/20 0.52
CHRM4 P08173 3/20 0.52
CHRM5 P08912 3/20 0.52
CHRM1 P11229 3/20 0.52
CHRM3 P20309 3/20 0.52
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
TSHR P16473 1/20 0.33
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
CA9 Q16790 2/20 0.32
CA12 O43570 1/20 0.32
POLB P06746 2/20 0.31
ALDH1A1 P00352 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
GAA P10253 1/20 0.31
CA4 P22748 1/20 0.31
FAAH O00519 1/20 0.31
MGLL Q99685 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17749049 0.78 CHRM2 (0.48) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL11726006 0.78 CHRM2 (0.48) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL6819115 0.78 CHRM2 (0.48) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL34663 0.76 CHRM2 (0.42) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL9031379 0.72 CHRM2 (0.59) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL5005449 0.72 HTR1A (0.41) CHRM2CHRM3MEN1KMT2APOLB
SCHEMBL8863095 0.71 POLB (0.43) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL8862946 0.71 CHRM2 (0.41) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL2639486 0.71 MGLL (0.50) ALDH1A1RAB9ASMN1; SMN2FAAHMGLL
SCHEMBL11724860 0.69 CHRM2 (1.00) CHRM2CHRM4CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105026432-A Aprotinin-derived polypeptide-antibody conjugates ANGIOCHEM INC 2015-11-04 CN claimed
CN-104781281-A Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin ANGIOCHEM INC 2015-07-15 CN claimed
EP-0941738-B1 Antigenic conjugates of conserved lipooligosaccharides of gram negative bacteria WYETH CORP (US) 2005-05-11 EP claimed
US-20040052804-A1 Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria WYETH HOLDINGS CORPORATION 2004-03-18 US claimed
US-6645503-B1 Eliciting a cross reactive immune response against heterologous strains of the gram negative bacteria; vaccines; comprises the inner core and lipid A portions of the lipopolysaccharide WYETH HOLDINGS CORPORATION 2003-11-11 US claimed
EP-0941738-A1 Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria American Cyanamid Company (US) 1999-09-15 EP claimed
EP-3935385-A1 METHODS FOR DETECTING AND QUANTIFYING MEMBRANE-ASSOCIATED PROTEINS ON EXTRACELLULAR VESICLES F. Hoffmann-La Roche AG (CH) 2022-01-12 EP disclosed
WO-2020185535-A1 METHODS FOR DETECTING AND QUANTIFYING MEMBRANE-ASSOCIATED PROTEINS ON EXTRACELLULAR VESICLES GENENTECH, INC. (US) 2020-09-17 WO disclosed
CN-110461354-A Protein conjugate TDW GROUP 2019-11-15 CN disclosed
CN-109071670-A Antibody and antibody fragment for locus specificity conjugation 辉瑞公司 2018-12-21 CN disclosed
CN-108135929-A System and method for continuous health monitoring using photo-enzymatic analyte sensors 梅特罗诺姆保健公司 2018-06-08 CN disclosed
CN-103747807-B P97-antibody conjugates and methods of use 比奥阿赛斯技术有限公司 2016-12-07 CN disclosed
CN-106110332-A Protein polymer drug conjugate 梅尔莎纳医疗公司 2016-11-16 CN disclosed
US-4416817-A BACTERICIDES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1983-11-22 US disclosed
EP-0021676-B1 3-METHOXY-2-OXOAZETIDINE DERIVATIVES AND THEIR PRODUCTION Takeda Chemical Industries, Ltd. (JP) 1983-09-14 EP disclosed
EP-0053815-A1 2-Oxoazetidine derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1982-06-16 EP disclosed
EP-0053387-A1 Method of preparing 1-sulfo-2-oxoazetidine derivatives and intermediates therefor Takeda Chemical Industries, Ltd. (JP) 1982-06-09 EP disclosed
EP-0050965-A1 Beta-lactamase inhibitory composition Takeda Chemical Industries, Ltd. (JP) 1982-05-05 EP disclosed
EP-0021676-A1 3-Methoxy-2-oxoazetidine derivatives and their production Takeda Chemical Industries, Ltd. (JP) 1981-01-07 EP disclosed
EP-0021678-A1 1-Sulpho-2-oxoazetidine derivatives, their production and pharmaceutical compositions thereof Takeda Chemical Industries, Ltd. (JP) 1981-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040052804-A1 Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria LY96, DDOST, LRBA CHRM2 4853/4885CHRM4 4768/4885CHRM5 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.